Literature DB >> 23152537

Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination.

Kieran Gillick1, Darja Pollpeter, Prabhjeet Phalora, Eun-Young Kim, Steven M Wolinsky, Michael H Malim.   

Abstract

The Vif protein of human immunodeficiency virus type 1 (HIV-1) promotes viral replication by downregulation of the cell-encoded, antiviral APOBEC3 proteins. These proteins exert their suppressive effects through the inhibition of viral reverse transcription as well as the induction of cytidine deamination within nascent viral cDNA. Importantly, these two effects have not been characterized in detail in human CD4(+) T cells, leading to controversies over their possible contributions to viral inhibition in the natural cell targets of HIV-1 replication. Here we use wild-type and Vif-deficient viruses derived from the CD4(+) T cells of multiple donors to examine the consequences of APOBEC3 protein function at natural levels of expression. We demonstrate that APOBEC3 proteins impart a profound deficiency to reverse transcription from the initial stages of cDNA synthesis, as well as excessive cytidine deamination (hypermutation) of the DNAs that are synthesized. Experiments using viruses from transfected cells and a novel method for mapping the 3' termini of cDNAs indicate that the inhibition of reverse transcription is not limited to a few specific sites, arguing that APOBEC3 proteins impede enzymatic processivity. Detailed analyses of mutation spectra in viral cDNA strongly imply that one particular APOBEC3 protein, APOBEC3G, provides the bulk of the antiviral phenotype in CD4(+) T cells, with the effects of APOBEC3F and APOBEC3D being less significant. Taken together, we conclude that the dual mechanisms of action of APOBEC3 proteins combine to deliver more effective restriction of HIV-1 than either function would by itself.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23152537      PMCID: PMC3554184          DOI: 10.1128/JVI.02587-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  80 in total

1.  Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.

Authors:  Edmund N C Newman; Rebecca K Holmes; Heather M Craig; Kevin C Klein; Jaisri R Lingappa; Michael H Malim; Ann M Sheehy
Journal:  Curr Biol       Date:  2005-01-26       Impact factor: 10.834

2.  Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G.

Authors:  Shari M Kaiser; Michael Emerman
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import.

Authors:  R A Fouchier; B E Meyer; J H Simon; U Fischer; M H Malim
Journal:  EMBO J       Date:  1997-08-01       Impact factor: 11.598

4.  The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: a role for Vif in determining virus host range and cross-species transmission.

Authors:  J H Simon; D L Miller; R A Fouchier; M A Soares; K W Peden; M H Malim
Journal:  EMBO J       Date:  1998-08-10       Impact factor: 11.598

5.  Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase.

Authors:  Bindong Liu; Phuong Thi Nguyen Sarkis; Kun Luo; Yunkai Yu; Xiao-Fang Yu
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

6.  The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes.

Authors:  J H Simon; M H Malim
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

7.  Role of Vif in human immunodeficiency virus type 1 reverse transcription.

Authors:  J Goncalves; Y Korin; J Zack; D Gabuzda
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

8.  Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates.

Authors:  Véronique Zennou; Paul D Bieniasz
Journal:  Virology       Date:  2006-02-07       Impact factor: 3.616

9.  Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1.

Authors:  P Sova; D J Volsky
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

10.  APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons.

Authors:  Hui Chen; Caroline E Lilley; Qin Yu; Darwin V Lee; Jody Chou; Iñigo Narvaiza; Nathaniel R Landau; Matthew D Weitzman
Journal:  Curr Biol       Date:  2006-03-07       Impact factor: 10.834

View more
  67 in total

1.  Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.

Authors:  Erez Pery; Ann Sheehy; N Miranda Nebane; Andrew Jay Brazier; Vikas Misra; Kottampatty S Rajendran; Sara J Buhrlage; Marie K Mankowski; Lynn Rasmussen; E Lucile White; Roger G Ptak; Dana Gabuzda
Journal:  J Biol Chem       Date:  2015-02-27       Impact factor: 5.157

Review 2.  Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

Authors:  Belete A Desimmie; Krista A Delviks-Frankenberrry; Ryan C Burdick; DongFei Qi; Taisuke Izumi; Vinay K Pathak
Journal:  J Mol Biol       Date:  2013-11-02       Impact factor: 5.469

3.  Feline Immunodeficiency Virus Vif N-Terminal Residues Selectively Counteract Feline APOBEC3s.

Authors:  Qinyong Gu; Zeli Zhang; Lucía Cano Ortiz; Ana Cláudia Franco; Dieter Häussinger; Carsten Münk
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

4.  APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.

Authors:  John F Krisko; Nurjahan Begum; Caroline E Baker; John L Foster; J Victor Garcia
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

5.  Nucleic acid recognition orchestrates the anti-viral response to retroviruses.

Authors:  Spyridon Stavrou; Kristin Blouch; Swathi Kotla; Antonia Bass; Susan R Ross
Journal:  Cell Host Microbe       Date:  2015-03-26       Impact factor: 21.023

Review 6.  APOBECs and virus restriction.

Authors:  Reuben S Harris; Jaquelin P Dudley
Journal:  Virology       Date:  2015-03-26       Impact factor: 3.616

7.  HIV restriction factor APOBEC3G binds in multiple steps and conformations to search and deaminate single-stranded DNA.

Authors:  Michael Morse; M Nabuan Naufer; Yuqing Feng; Linda Chelico; Ioulia Rouzina; Mark C Williams
Journal:  Elife       Date:  2019-12-18       Impact factor: 8.140

8.  Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus.

Authors:  John S Albin; William L Brown; Reuben S Harris
Journal:  Virology       Date:  2013-12-20       Impact factor: 3.616

Review 9.  The spectrum of APOBEC3 activity: From anti-viral agents to anti-cancer opportunities.

Authors:  Abby M Green; Matthew D Weitzman
Journal:  DNA Repair (Amst)       Date:  2019-09-13

10.  APOBEC3 inhibition of mouse mammary tumor virus infection: the role of cytidine deamination versus inhibition of reverse transcription.

Authors:  Alyssa L MacMillan; Rahul M Kohli; Susan R Ross
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.